The role of artesunate for the treatment of urinary schistosomiasis in schoolchildren: a systematic review and meta-analysis

References

• Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411–25.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Afifi AA, Adam I. High prevalence of Schistosoma haematobium infection in Gereida Camp, in southern Darfur, Sudan. Ann Trop Med Parasitol. 2009;103(8):741–3.
   PubMed Web of Science ®Google Scholar
• Ekpo UF, Laja-Deile A, Oluwole AS, Sam-Wobo SO, Mafiana CF. Urinary schistosomiasis among preschool children in a rural community near Abeokuta, Nigeria. Parasit Vectors. 2010;3:58.
   PubMed Web of Science ®Google Scholar
• King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet. 2005;365(9470):1561–9.
   PubMed Web of Science ®Google Scholar
• King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop. 2010;113(2):95–104.
   PubMed Web of Science ®Google Scholar
• Mostafa MH, Sheweita SA, O’Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. 1999;12(1):97–111.
   PubMed Web of Science ®Google Scholar
• Danso-Appiah A, Utzinger J, Liu J, Olliaro P. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev. 2008;(3):CD000053.
   Google Scholar
• Greenberg RM. Are Ca2+ channels targets of praziquantel action? Int J Parasitol. 2005;35(1):1–9.
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659–67.
   PubMed Web of Science ®Google Scholar
• Gray DJ, Ross AG, Li YS, McManus DP. Diagnosis and management of schistosomiasis. BMJ. 2011;342:d2651.
   PubMed Web of Science ®Google Scholar
• Olliaro PL, Vaillant MT, Belizario VJ, Lwambo NJ, Ouldabdallahi M, Pieri OS, et al.. A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis. 2011;5(6):e1165.
   Web of Science ®Google Scholar
• Dietze R, Prata A. Rate of reversion of hepatosplenic schistosomiasis after specific therapy. Rev Soc Bras Med Trop. 1986;19(2):69–73.
   PubMedGoogle Scholar
• Doehring-Schwerdtfeger E, Abdel-Rahim IM, Kardorff R, Kaiser C, Franke D, Schlake J, et al.. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty-three months after treatment with praziquantel. Am J Trop Med Hyg. 1992;46(4):409–15.
   PubMed Web of Science ®Google Scholar
• Gryseels B. The relevance of schistosomiasis for public health. Trop Med Parasitol. 1989;40(2):134–42.
   PubMedGoogle Scholar
• Richter J. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies. Acta Trop. 2000;77(1):111–31.
   PubMed Web of Science ®Google Scholar
• Hatz CF, Vennervald BJ, Nkulila T, Vounatsou P, Kombe Y, Mayombana C, et al.. Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania. Am J Trop Med Hyg. 1998;59(5):775–81.
   PubMed Web of Science ®Google Scholar
• Olds GR. Administration of praziquantel to pregnant and lactating women. Acta Trop. 2003;86(2–3):185–95.
   PubMed Web of Science ®Google Scholar
• WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. World Health Organ Tech Rep Ser. 2002;912:i–vi1–57, back cover.
   PubMedGoogle Scholar
• Danso-Appiah A, de Vlas SJ. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol. 2002;18(3):125–9.
   PubMed Web of Science ®Google Scholar
• Alonso D, Munoz J, Gascon J, Valls ME, Corachan M. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg. 2006;74(2):342–4.
   PubMed Web of Science ®Google Scholar
• Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, et al.. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg. 1999;60(6):932–5.
   PubMed Web of Science ®Google Scholar
• Messerli SM, Kasinathan RS, Morgan W, Spranger S, Greenberg RM. Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol Biochem Parasitol. 2009;167(1):54–9.
   PubMed Web of Science ®Google Scholar
• Kasinathan RS, Goronga T, Messerli SM, Webb TR, Greenberg RM. Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel. FASEB J. 2010;24(1):128–35.
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: WHO; 2010.
   Google Scholar
• Utzinger J, Xiao S, Keiser J, Chen M, Zheng J, Tanner M. Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites. Curr Med Chem. 2001;8(15):1841–60.
   PubMed Web of Science ®Google Scholar
• Adam I, Elhardello OA, Elhadi MO, Abdalla E, Elmardi KA, Jansen FH. The antischistosomal efficacies of artesunate–sulfamethoxypyrazine–pyrimethamine and artemether–lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria. Ann Trop Med Parasitol. 2008;102(1):39–44.
   PubMed Web of Science ®Google Scholar
• Boulanger D, Dieng Y, Cisse B, Remoue F, Capuano F, Dieme JL, et al.. Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Trans R Soc Trop Med Hyg. 2007;101(2):113–6.
   PubMed Web of Science ®Google Scholar
• Liu R, Dong HF, Guo Y, Zhao QP, Jiang MS. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasit Vectors. 2011;4:201.
   PubMed Web of Science ®Google Scholar
• Shuhua X, Jiqing Y, Jinying M, Huifang G, Peiying J, Tanner M. Effect of praziquantel together with artemether on Schistosoma japonicum parasites of different ages in rabbits. Parasitol Int. 2000;49(1):25–30.
   PubMed Web of Science ®Google Scholar
• Xiao S, Utzinger J, Chollet J, Endriss Y, N’Goran EK, Tanner M. Effect of artemether against Schistosoma haematobium in experimentally infected hamsters. Int J Parasitol. 2000;30(9):1001–6.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman D. Assessing risk of bias in included studies. In: Higgins J, Green S, editors. Cochrane handbook of systematic reviews of interventions. Chichester: John Wiley & Sons; 2008, 187–241.
   Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
   PubMed Web of Science ®Google Scholar
• Borrmann S, Szlezak N, Faucher JF, Matsiegui PB, Neubauer R, Binder RK, et al.. Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J Infect Dis. 2001;184(10):1363–6.
   PubMed Web of Science ®Google Scholar
• de Clercq D, Vercruysse J, Kongs A, Verle P, Dompnier JP, Faye PC. Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren. Acta Trop. 2002;82(1):61–6.
   PubMed Web of Science ®Google Scholar
• Sissoko MS, Dabo A, Traore H, Diallo M, Traore B, Konate D, et al.. Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS ONE. 2009;4(10):e6732.
   Web of Science ®Google Scholar
• Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang-Etoh EC. Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria. Trans R Soc Trop Med Hyg. 2009;103(1):38–44.
   PubMed Web of Science ®Google Scholar
• Keiser J, N’Guessan NA, Adoubryn KD, Silue KD, Vounatsou P, Hatz C, et al.. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis. 2010;50(9):1205–13.
   PubMed Web of Science ®Google Scholar
• Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368(9541):1106–18.
   PubMed Web of Science ®Google Scholar
• White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1999;354(1384):739–49.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
   PubMed Web of Science ®Google Scholar
• Utzinger J, N’Goran EK, N’Dri A, Lengeler C, Xiao S, Tanner M. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet. 2000;355(9212):1320–5.
   PubMed Web of Science ®Google Scholar
• Li YS, Chen HG, He HB, Hou XY, Ellis M, McManus DP. A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop. 2005;96(2–3):184–90.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wong CM. Evaluation of the 1992–1999 World Bank Schistosomiasis Control Project in China. Acta Trop. 2003;85(3):303–13.
   PubMed Web of Science ®Google Scholar
• Magnussen P. Treatment and re-treatment strategies for schistosomiasis control in different epidemiological settings: a review of 10 years’ experiences. Acta Trop. 2003;86(2–3):243–54.
   PubMed Web of Science ®Google Scholar
• Minai M, Hosaka Y, Ohta N. Historical view of schistosomiasis japonica in Japan: implementation and evaluation of disease-control strategies in Yamanashi Prefecture. Parasitol Int. 2003;52(4):321–6.
   PubMed Web of Science ®Google Scholar